Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Shenzhen Salubris Pharmaceuticals Co Ltd (002294)

Shenzhen
Currency in CNY
Disclaimer
28.87
+0.96(+3.44%)
Closed
Fair Value
Unlock Value
Day's Range
27.5329.15
52 wk Range
23.5038.29
Bid/Ask
28.87 / 28.87
Prev. Close
27.91
Open
28.18
Day's Range
27.53-29.15
52 wk Range
23.5-38.29
Volume
7,040,349
Average Volume (3m)
5,208,417
1-Year Change
-21.23%
Shares Outstanding
1,091,359,012
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
37.00
Upside +28.16%

People Also Watch

17.48
ONB
+0.40%
104.50
WTFC
-0.17%
106.69
FELE
+0.05%
124.33
ENSG
-1.03%
404.39
ERIE
-0.93%
How do you feel today about 002294?
Vote to see community's results!
or

Salubris Pharm A Company Profile

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiology, and cardiac rhythm management. In addition, the company develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in phase III clinical trial for treatment of hypertension; Enarodustat, a drug for renal anemia; SAL056 medicine used for treating osteoporosis; and Fotagliptin and SAL015 for diabetes which are under phase III clinical trial. Further, it develops Sacubitril Allisartan Calcium and SAL007 medicine for chronic heart failure; SAL003 medicine that is in phase I clinical trial to treat hypercholesterolemia; and SAL0114 for depressant indications. Additionally, the company’s preclinical products are SAL023 for osteoporosis; SAL0112 to treat diabetes; and SAL008 for the treatment of tumors. Furthermore, it develops medical devices, such as intracranial segment of vertebral artery stent, which is under clinical trials for Neurology intervention; SaExtenVena cava filter and Microneedle perfusion absolute ethanol delivery system used for Peripheral vascular intervention; and LAMax LAAC Left Atrial Appendage Occluder that is in clinical trials used for Structural heart disease. The company was founded in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. is an operating subsidiary of Salubris Pharmaceuticals Co., Ltd.

Employees
3454
Market
China
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.